Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ODC1

Gene summary for ODC1

Gene summary.

Gene information	Species	Human
	Gene symbol	ODC1
	Gene ID	4953
	Gene name	ornithine decarboxylase 1
	Gene Alias	BABS
	Cytomap	2p25.1
	Gene Type	protein-coding
	GO ID	GO:0006082
	UniProtAcc	B4DXF8

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
4953	ODC1	CA_HPV_1	Human	Cervix	CC	2.55e-03	-5.71e-02	0.0264
4953	ODC1	CA_HPV_3	Human	Cervix	CC	1.05e-04	4.01e-01	0.0414
4953	ODC1	HTA11_78_2000001011	Human	Colorectum	AD	1.83e-03	2.52e-01	-0.1088
4953	ODC1	HTA11_347_2000001011	Human	Colorectum	AD	1.01e-12	3.63e-01	-0.1954
4953	ODC1	HTA11_696_2000001011	Human	Colorectum	AD	1.63e-04	2.17e-01	-0.1464
4953	ODC1	HTA11_1391_2000001011	Human	Colorectum	AD	3.41e-10	5.23e-01	-0.059
4953	ODC1	HTA11_866_3004761011	Human	Colorectum	AD	3.45e-08	3.41e-01	0.096
4953	ODC1	HTA11_10623_2000001011	Human	Colorectum	AD	4.32e-02	2.93e-01	-0.0177
4953	ODC1	HTA11_6801_2000001011	Human	Colorectum	SER	9.43e-06	7.21e-01	0.0171
4953	ODC1	HTA11_7696_3000711011	Human	Colorectum	AD	1.13e-11	3.42e-01	0.0674
4953	ODC1	HTA11_7469_2000001011	Human	Colorectum	AD	1.38e-02	4.71e-01	-0.0124
4953	ODC1	HTA11_6818_2000001021	Human	Colorectum	AD	8.84e-05	2.85e-01	0.0588
4953	ODC1	HTA11_99999970781_79442	Human	Colorectum	MSS	8.35e-26	6.53e-01	0.294
4953	ODC1	HTA11_99999965062_69753	Human	Colorectum	MSI-H	2.31e-12	1.55e+00	0.3487
4953	ODC1	HTA11_99999965104_69814	Human	Colorectum	MSS	6.48e-32	1.13e+00	0.281
4953	ODC1	HTA11_99999971662_82457	Human	Colorectum	MSS	6.82e-39	8.60e-01	0.3859
4953	ODC1	HTA11_99999973899_84307	Human	Colorectum	MSS	5.27e-14	7.85e-01	0.2585
4953	ODC1	HTA11_99999974143_84620	Human	Colorectum	MSS	1.19e-16	4.48e-01	0.3005
4953	ODC1	A015-C-005	Human	Colorectum	FAP	5.77e-07	4.92e-01	-0.0336
4953	ODC1	LZE7T	Human	Esophagus	ESCC	4.78e-02	8.25e-01	0.0667

Page: 1 2 3 4 5 6 7 8

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Skin		AK: Actinic keratosis
		cSCC: Cutaneous squamous cell carcinoma
		SCCIS:squamous cell carcinoma in situ
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:004217610	Cervix	CC	regulation of protein catabolic process	104/2311	391/18723	9.39e-15	9.36e-12	104
GO:00096158	Cervix	CC	response to virus	73/2311	367/18723	2.22e-05	3.95e-04	73
GO:0042176	Colorectum	AD	regulation of protein catabolic process	160/3918	391/18723	1.06e-19	7.34e-17	160
GO:0006520	Colorectum	AD	cellular amino acid metabolic process	81/3918	284/18723	1.37e-03	1.19e-02	81
GO:00421761	Colorectum	SER	regulation of protein catabolic process	126/2897	391/18723	5.33e-17	2.52e-14	126
GO:00065201	Colorectum	SER	cellular amino acid metabolic process	61/2897	284/18723	4.20e-03	3.41e-02	61
GO:00421762	Colorectum	MSS	regulation of protein catabolic process	145/3467	391/18723	2.03e-18	1.17e-15	145
GO:0006596	Colorectum	MSS	polyamine biosynthetic process	7/3467	14/18723	7.51e-03	4.72e-02	7
GO:00421763	Colorectum	MSI-H	regulation of protein catabolic process	65/1319	391/18723	6.96e-11	1.29e-08	65
GO:1901605	Colorectum	MSI-H	alpha-amino acid metabolic process	26/1319	195/18723	1.26e-03	2.02e-02	26
GO:0009615	Colorectum	MSI-H	response to virus	40/1319	367/18723	3.99e-03	4.61e-02	40
GO:00421764	Colorectum	FAP	regulation of protein catabolic process	106/2622	391/18723	5.00e-12	3.06e-09	106
GO:0042176111	Esophagus	ESCC	regulation of protein catabolic process	280/8552	391/18723	8.65e-26	2.39e-23	280
GO:000961518	Esophagus	ESCC	response to virus	238/8552	367/18723	6.65e-14	3.32e-12	238
GO:004217612	Liver	Cirrhotic	regulation of protein catabolic process	181/4634	391/18723	7.94e-21	2.77e-18	181
GO:19016051	Liver	Cirrhotic	alpha-amino acid metabolic process	82/4634	195/18723	7.72e-08	2.30e-06	82
GO:000652011	Liver	Cirrhotic	cellular amino acid metabolic process	103/4634	284/18723	8.88e-06	1.30e-04	103
GO:00096155	Liver	Cirrhotic	response to virus	126/4634	367/18723	2.10e-05	2.77e-04	126
GO:0006595	Liver	Cirrhotic	polyamine metabolic process	12/4634	18/18723	2.07e-04	1.90e-03	12
GO:00065962	Liver	Cirrhotic	polyamine biosynthetic process	10/4634	14/18723	3.11e-04	2.72e-03	10

Page: 1 2 3 4

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa00330	Colorectum	AD	Arginine and proline metabolism	23/2092	50/8465	8.27e-04	5.90e-03	3.76e-03	23
hsa00480	Colorectum	AD	Glutathione metabolism	23/2092	57/8465	6.52e-03	2.76e-02	1.76e-02	23
hsa003301	Colorectum	AD	Arginine and proline metabolism	23/2092	50/8465	8.27e-04	5.90e-03	3.76e-03	23
hsa004801	Colorectum	AD	Glutathione metabolism	23/2092	57/8465	6.52e-03	2.76e-02	1.76e-02	23
hsa003304	Colorectum	MSS	Arginine and proline metabolism	23/1875	50/8465	1.52e-04	1.24e-03	7.61e-04	23
hsa004802	Colorectum	MSS	Glutathione metabolism	22/1875	57/8465	3.58e-03	1.64e-02	1.01e-02	22
hsa003305	Colorectum	MSS	Arginine and proline metabolism	23/1875	50/8465	1.52e-04	1.24e-03	7.61e-04	23
hsa004803	Colorectum	MSS	Glutathione metabolism	22/1875	57/8465	3.58e-03	1.64e-02	1.01e-02	22
hsa003306	Colorectum	FAP	Arginine and proline metabolism	16/1404	50/8465	5.33e-03	2.10e-02	1.27e-02	16
hsa003307	Colorectum	FAP	Arginine and proline metabolism	16/1404	50/8465	5.33e-03	2.10e-02	1.27e-02	16
hsa0048018	Esophagus	ESCC	Glutathione metabolism	44/4205	57/8465	1.81e-05	9.03e-05	4.63e-05	44
hsa0048019	Esophagus	ESCC	Glutathione metabolism	44/4205	57/8465	1.81e-05	9.03e-05	4.63e-05	44
hsa004809	Liver	Cirrhotic	Glutathione metabolism	30/2530	57/8465	2.63e-04	1.72e-03	1.06e-03	30
hsa003308	Liver	Cirrhotic	Arginine and proline metabolism	25/2530	50/8465	2.18e-03	9.41e-03	5.80e-03	25
hsa0048012	Liver	Cirrhotic	Glutathione metabolism	30/2530	57/8465	2.63e-04	1.72e-03	1.06e-03	30
hsa0033011	Liver	Cirrhotic	Arginine and proline metabolism	25/2530	50/8465	2.18e-03	9.41e-03	5.80e-03	25
hsa0048022	Liver	HCC	Glutathione metabolism	42/4020	57/8465	5.00e-05	2.62e-04	1.46e-04	42
hsa0033021	Liver	HCC	Arginine and proline metabolism	33/4020	50/8465	6.28e-03	1.77e-02	9.83e-03	33
hsa0048032	Liver	HCC	Glutathione metabolism	42/4020	57/8465	5.00e-05	2.62e-04	1.46e-04	42
hsa0033031	Liver	HCC	Arginine and proline metabolism	33/4020	50/8465	6.28e-03	1.77e-02	9.83e-03	33

Page: 1 2

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ODC1

SNV

Missense_Mutation

novel

c.867N>G

p.Asn289Lys

p.N289K

P11926

protein_coding

deleterious(0.03)

possibly_damaging(0.779)

TCGA-AN-A0FN-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

ODC1

SNV

Missense_Mutation

novel

c.1306N>C

p.Thr436Pro

p.T436P

P11926

protein_coding

tolerated(0.41)

benign(0)

TCGA-D8-A1JA-01

Breast

breast invasive carcinoma

Female

<65

III/IV

Chemotherapy

adriamycin

ODC1

insertion

Frame_Shift_Ins

novel

c.868_869insCGGAAGCCCCATCCTCCCAT

p.Ile290ThrfsTer15

p.I290Tfs*15

P11926

protein_coding

TCGA-AN-A0FN-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

ODC1

deletion

Frame_Shift_Del

novel

c.335delA

p.Asn112IlefsTer19

p.N112Ifs*19

P11926

protein_coding

TCGA-D8-A27V-01

Breast

breast invasive carcinoma

Female

<65

I/II

Hormone Therapy

tamoxiphen

ODC1

SNV

Missense_Mutation

novel

c.484G>A

p.Ala162Thr

p.A162T

P11926

protein_coding

deleterious(0.05)

benign(0.3)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

ODC1

SNV

Missense_Mutation

rs759064940

c.638N>G

p.Ser213Cys

p.S213C

P11926

protein_coding

deleterious(0)

possibly_damaging(0.658)

TCGA-C5-A1MH-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Chemotherapy

cisplatin

ODC1

SNV

Missense_Mutation

novel

c.380N>A

p.Gly127Glu

p.G127E

P11926

protein_coding

deleterious(0.04)

probably_damaging(0.99)

TCGA-C5-A2LZ-01

Cervix

cervical & endocervical cancer

Female

>=65

III/IV

Unknown

ODC1

SNV

Missense_Mutation

rs368830902

c.355C>G

p.Gln119Glu

p.Q119E

P11926

protein_coding

deleterious(0.01)

benign(0.056)

TCGA-C5-A7UI-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

ODC1

SNV

Missense_Mutation

novel

c.1058N>T

p.Ser353Phe

p.S353F

P11926

protein_coding

deleterious(0)

possibly_damaging(0.516)

TCGA-EA-A3HU-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

ODC1

SNV

Missense_Mutation

rs745661230

c.199N>A

p.Ala67Thr

p.A67T

P11926

protein_coding

tolerated(0.23)

probably_damaging(0.981)

TCGA-AA-3715-01

Colorectum

colon adenocarcinoma

Male

>=65

I/II

Unknown

Page: 1 2 3 4 5

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID	Symbol	Category	Interaction Types	Drug Claim Name	Drug Name	PMIDs
4953	ODC1	DRUGGABLE GENOME, ENZYME	inhibitor	CHEMBL1201037	EFLORNITHINE HYDROCHLORIDE
4953	ODC1	DRUGGABLE GENOME, ENZYME		Eflornithine	EFLORNITHINE
4953	ODC1	DRUGGABLE GENOME, ENZYME	inhibitor	178101866	EFLORNITHINE
4953	ODC1	DRUGGABLE GENOME, ENZYME		VINCRISTINE	VINCRISTINE	19006285
4953	ODC1	DRUGGABLE GENOME, ENZYME	inhibitor	178101831
4953	ODC1	DRUGGABLE GENOME, ENZYME		EFLORNITHINE	EFLORNITHINE
4953	ODC1	DRUGGABLE GENOME, ENZYME		Difluoromethylornithine

Page: 1